THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

~~1. Use of a compound of the formulae:~~





~~or~~

~~wherein:~~

~~X is selected from the group consisting of:~~







~~;~~ ~~;~~ ~~and~~



~~;~~

~~R_1 to R_9 are independently C, N, O or S;~~

~~R_{10} is independently selected from C_{1-6}alkyl, halo, carboxylic acid, amino, hydroxy and C_{1-6}alkoxy;~~

~~Y is A, CH_2-A or CH=A;~~

~~A is selected from:~~



and ;

~~Z is selected from the group consisting of:~~



,


,


,



,


,


,



,


,



,


,





~~and~~ ;

~~R_{11} is independently selected from halo, alkyl, hydroxy, amino and substituted amino of the formula $-NHR_{16}$ and wherein:~~

~~R_{16} is selected from -CN, $-SO_2(R_{17})_aR_{18}$ and $-CO(R_{17})_aR_{18}$,~~

~~a is 0 or 1,~~

~~R_{17} is selected from -NH- and -O-, and~~

~~R_{18} is selected from -H, $-CH_3$, $-CH_2CH_3$, $-CH_2OH$ and $-CH_2CH_2OH$;~~

R_{12}, R_{14} and R_{15} are independently C, CH, CH_2, O, N, NH or S;
R_{13} is C, CH, CH_2, N, NH, C-CF_3, CH-CF_3 or C=O;
m is 0, 1, 2, 3, 4 or 5; and
n is 0, 1, 2, 3 or 4,
or a stereoisomer or pharmaceutically acceptable salt thereof,
for the manufacture of a medicament for:

- the therapeutic treatment of hypertension or prehypertension; or
- the prophylactic treatment of myocardial fibrosis; or
- the therapeutic treatment of myocardial fibrosis; or
- the therapeutic treatment of hypertension and myocardial fibrosis; or
- the treatment of prehypertension and myocardial fibrosis.

2. The use according to claim 1 wherein R_{10} is independently selected from -CH_3, -C(O)OH, -F, -NH_2, -OH and -OCH_3.

3. The use according to claim 1, wherein R_5 to R_9 are independently C or N.

4. The use according to any one of claims 1 to 3, wherein R_{11} is halo selected from the group consisting of F, Cl, Br and I.

5. The use according to any one of claims 1 to 3, wherein R_{11} is substituted amino selected from the group consisting of -$NHSO_2CH_3$, -NHCOH, -$NHCONHCH_3$, -$NHCONHCH_2CH_3$, -$NHSO_2NHCH_3$, -$NHSO_2NHCH_2CH_3$, -$NHCOCH_3$, -$NHCOOCH_3$, -$NHCOOCH_2CH_2OH$, -$NHCONH_2$ and -NHCN.

6. The use according to any one of claims 1 to 3, wherein R_{11} is alkyl selected from the group consisting of methyl, ethyl, propyl, butyl and pentyl.

7. The use according to any one of claims 1 to 6, wherein the compound is selected from the group consisting of:














O
NH2
N
N
NH
MeHN
O


N
N
OH
H
N
O
MeHN


N
H2N
O
N
HN
MeHN
O


O
NH2
N
N
NH
EtHN
O


N
N
OH
H
N
O
EtHN


N
H2N
O
N
HN
EtHN
O


O
NH2
N
N
NH
MeHN
S
O
O


N
N
OH
H
N
S
O
O
MeHN


N
H2N
O
N
HN
MeHN
S
O
O


O
N
N
NH2
NH
EtHN
S
O
O


N
OH
N
H
N
O
S
O
EtHN


N
H2N
O
N
HN
EtHN
S
O
O


O
N
N
NH2
NH
O


N
OH
N
H
N
O


N
H2N
O
N
HN
O


O
N
N
NH2
NH
O
O


N
OH
N
H
N
O
O


N
H2N
O
N
HN
O
O
























O
N
N
NH2
N
H

,


N
N
OH
N
H

,


H2N
O
N
N
N
H

,


O
N
N
NH2
H
N

,


N
OH
N
HN

,


N
H2N
N
O
H
N

,












































































O
NH2
N
N
N
N
H


N
N
OH
N
N
H


H2N
O
N
N
N
N
H


O
NH2
N
N
N
N
H


OH
N
N
N
N
H


H2N
O
N
N
N
N
H


O
NH2
N
N
N
N
H


N
N
OH
N
N
H


H2N
O
N
N
N
N
H
































O
NH2
N
N
H2N
N


N
N
OH
H2N
N


N
H2N
O
N
H2N
N


O
NH2
N
N
F
F
HO


N
N
OH
F
HO
F


N
H2N
O
N
F
F
OH


O
NH2
N
N
F
HO


N
N
OH
F
HO


N
H2N
O
N
F
OH


O
N
NH2
N
F
HO


N
N
F
OH
HO


N
H2N
O
N
F
HO


O
N
NH2
N
HO
F


N
N
OH
HO
F


N
H2N
O
N
HO
F


O
N
NH2
N
HO
F


N
N
OH
HO
F


N
H2N
O
N
HO
F


O
N
NH2
N
F
HO

,


N
N
OH
HO
F

,


N
H2N
O
N
F
HO

,


O
N
NH2
N
HO
OH

,


N
N
OH
HO
OH

,


N
H2N
O
N
HO
OH

,


O
N
NH2
N
HO
OH
F

,


N
N
OH
HO
F
OH

,


N
H2N
O
N
HO
OH
F

,


O
N
N
NH2
HO
OH
Cl


N
N
OH
HO
Cl
OH


N
H2N
O
N
HO
OH
Cl


O
N
N
NH2
MeO2SHN
NHSO2Me


N
N
OH
MeO2SHN
NHSO2Me


N
H2N
O
N
MeO2SHN
NHSO2Me


N
N
O
N
H2N
OH


N
N
OH
N
OH


N
N
H2N
O
N
HO


N
N
N
O
H_2N
OH

,


N
N
N
OH
OH

,


N
N
H_2N
O
N
N
HO

;


N
N
N
O
H_2N
OH

,


N
N
N
OH
OH

,


N
N
H_2N
O
N
N
HO

;


N
N
N
O
H_2N
OH

,


N
N
N
OH
OH

,


N
N
H_2N
O
N
N
HO

;














N
N
O
H2N
OH


N
N
OH
OH


N
H2N
O
N
HO


OH
N
N
O
H2N
OH


HO
N
N
OH
OH


HO
N
H2N
O
N
HO


F
N
N
O
H2N
OH


F
N
N
OH
OH


F
N
H2N
O
N
HO














O
N
N
O
H_2N
OH
,


O
N
N
OH
OH
,


O
N
H_2N
N
O
HO
,


N
N
O
H_2N
OH
,


N
N
OH
OH
,


N
N
H_2N
N
O
HO
,


N
NH
N
O
H_2N
OH
,


N
NH
OH
N
OH
,


H
N
N
N
H_2N
N
O
HO
,


N
S
N
O
N
H2N
OH

,


N
S
OH
N
N
OH

,


N
S
N
H2N
O
N
HO

,


O
N
N
O
N
H2N
OH

,


N
O
OH
N
N
OH

,


N
O
N
H2N
O
N
HO

,


N
N
N
O
N
H2N
OH

,


N
N
OH
N
N
OH

,


N
N
N
H2N
O
N
HO

,














H
N
N
N
O
N
H2N
OH

,


N
NH
N
OH
N
OH

,


H
N
N
N
H2N
O
N
HO

,


N
OH
N
OH

,


N
NH2
N
O
OH

,


NH2
N
O
N
HO

,


O
N
NH2
N
OH

,


N
NH2
N
O
OH

,


N
HO
N
HO

,












N
N
O
NH
OH


N
N
NH
O
OH


N
O
H
N
N
HO


N
NH
N
O
OH


O
H
N
N
N
HO


N
O
N
NH
HO


N
N
O
NH
O
OH


N
N
O
NH
O
OH


N
O
H
N
O
N
HO


O
NH
O
N
N
OH


O
NH
O
N
N
HO


N
O
N
NH
O
HO


O
N
N
NH
O
OH


N
O
N
NH
O
OH


N
O
H
N
O
N
HO


O
NH
O
N
N
OH


O
NH
O
N
N
HO


N
O
N
NH
O
HO












,

,

,

,

,

,

,

,

,












N
O
NH2
N
OH


N
N
O
NH2
OH


N
N
O
NH2
HO


N
OH
O
N
OH


N
O
N
OH
OH


N
O
N
OH
HO


OH
N
O
N
OH


OH
N
O
N
HO


N
O
N
OH
HO


N
N
OH
OH


N
N
OH
OH


N
N
OH
HO


N
N
OH
OH


N
N
OH
HO


N
N
OH
HO


N
N
O
N
O
O
OH


N
N
O
N
O
O
OH


N
N
O
N
O
O
HO





~~,~~ ~~and~~



~~.~~

~~8. The use according to any one of claims 1 to 6, wherein the compound is selected from:~~







~~,~~ ~~and~~ ~~.~~

~~9~~1. A compound selected from the group consisting of:












,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,














,

,



,

,

,


,

,

,


O
NH2
N
N
N
H

,


N
N
OH
N
H

,


H2N
O
N
N
N
H

,


O
NH2
N
N
H
N

,


N
OH
N
HN

,


N
H2N
O
N
H
N

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,












O
NH2
N
N
F
HO
,

N
N
F
HO
OH
,

H2N
O
N
N
F
HO
,

O
NH2
N
N
HO
F
,

N
N
HO
OH
F
,

H2N
O
N
N
HO
F
,

O
NH2
N
N
HO
F
,

N
N
HO
OH
F
,

H2N
O
N
N
HO
F
,












,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


HO
O
N
N
O
H2N
OH
,

HO
O
OH
N
N
OH
,

HO
O
N
H2N
O
N
HO
,

F
N
O
H2N
N
OH
,

F
N
OH
N
OH
,

F
N
H2N
O
N
HO
,

NH2
N
O
H2N
N
OH
,

NH2
N
OH
N
OH
,

NH2
N
H2N
O
N
HO
,












O
N
N
O
H2N
OH
,

O
N
N
OH
OH
,

O
N
H2N
N
O
HO
,

F
F
N
N
O
H2N
OH
,

F
F
OH
N
N
OH
,

F
F
N
H2N
N
O
HO
,

S
N
N
O
H2N
OH
,

S
OH
N
N
OH
,

S
N
H2N
N
O
HO
,














,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


N
N
O
NH
OH
,

N
N
NH
O
OH
,

N
N
O
H
N
HO
,

N
N
NH
O
OH
,

O
H
N
N
N
HO
,

N
N
O
NH
HO
,

N
N
O
NH
O
OH
,

N
N
O
NH
O
OH
,

N
N
O
H
N
O
HO
,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


N
N
O
NH2
OH
,

N
N
O
NH2
OH
,

N
N
O
NH2
HO
,

N
N
OH
O
OH
,

N
N
O
OH
OH
,

N
N
O
OH
HO
,

N
N
OH
O
OH
,

N
N
OH
O
HO
,

N
N
O
OH
HO
,


N
N
OH
OH
,

N
N
OH
OH
,

N
N
OH
HO
,

OH
N
N
OH
,

OH
N
N
HO
,

N
N
OH
HO
,

N
N
O
N
O
O
OH
,

N
N
O
N
O
O
OH
,

N
N
O
N
O
O
HO
,



,


and


,

or a stereoisomer or pharmaceutically acceptable salt thereof.

~~10~~2. A compound selected from:



,


and


,

or a stereoisomer or pharmaceutically acceptable salt thereof.

~~11~~3. A pharmaceutical composition comprising a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim ~~9~~ 1 or claim ~~10~~2, and a pharmaceutically-acceptable excipient.

4. Use of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1 or claim 2, for the manufacture of a medicament for the therapeutic treatment of hypertension or prehypertension.

5. Use of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1 or claim 2, for the manufacture of a medicament for the prophylactic treatment of myocardial fibrosis.

6. Use of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1 or claim 2, for the manufacture of a medicament for the therapeutic treatment of myocardial fibrosis.

7. Use of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1 or claim 2, for the manufacture of a medicament for the therapeutic treatment of hypertension and myocardial fibrosis.

8. Use of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1 or claim 2, for the manufacture of a medicament for the treatment of prehypertension and myocardial fibrosis.